Celltrion Inc.

Bio-fd&c Co., Ltd.

Shin Jae Chang

Kye Sook Yi

Hyun Joo Lee

Seung Suh Hong

Jung Yun Kim

Joo Hyuck Lim

Jong Mook Kim

Min Seok Chang

Jae Won Jeon

Byung Pil Lim

Hyeong Mi Kim

Soo Young Lee

Pan Kyeom Kim

Jung Sun Ahn

Hwang Keun Jun

Sung Ho Moon

Jae Won Lee

Sung Hwan Kim

Young Jun Park

Ki Sung Kwon

Soo Yun Kim

Yeon Sook Kim

Jin Kyo Jeong

So Jung Lee

Jae Hun Kim

Seung Ki Lee

Eun Joo Cho

Ju Yeon Kim

Hyo Hyun Seo

Sang Hyun Moh

Man Ki Song

Eun Beom Lee

Eun Bee Park

Min Soo Kim

Ji Young Shin

Jong Moon Cho

Man Su Kim

Ji Hong Moh

Myung Sam Cho

Sang Tae Park

Jung Yeon Kim

Cheol Min Kim

Hwa Jin Lee

Joon Sun Yoon

Sun Ju Keum

Jeong Gon Park

Jung Ah Choi

Min Joo Choo

Jung Soo Bae

Won Kang Moon

Hyun Nam Song

Seon Kyung Park

The present invention relates to an expression cassette for a target protein, comprising a promoter, a polynucleotide coding for the target protein, an intron sequence, and a poly A sequence, an expression vector, and a transformant. The expression cassette for a target protein according to the present invention can simultaneously perform the expression of the intron sequence and the target protein through one transduction and exhibits the effect of inducing the high expression and high functionality of the target protein by regulating the expression of an endogenous gene.

Expression cassette for production of high-expression and high-functionality target protein and use thereof

The present invention relates tocallus having an increased content of gallic acid or an extract thereof and to a method for preparing the same. Thecallus extract according to the present invention has an excellent whitening effect by containing a large amount of gallic acid, and thus can be advantageously used as a cosmetic composition.

callus extract having increased content of gallic acid, method for preparing same, and whitening cosmetic composition containing same

This invention relates to a rabies virus G protein epitope and a rabies-virus-neutralizing binding molecule that binds specifically thereto, wherein different epitope sites of rabies virus G protein are identified and binding molecules that bind thereto and a cocktail thereof can be found to retain neutralizing activity against various rabies viruses.

Rabies virus G protein epitope, and rabies virus neutralising binding molecule that binds specifically thereto

The present invention provides a composition comprising at least two influenza A virus-neutralizing binding molecules that bind to an epitope in the stem region of influenza A virus hemagglutinin (HA) protein, the method comprising: i) a first binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H2, H5 and H9; ii) a second binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H3, H5, H7 and H9. The mixed composition of the present invention can effectively neutralize the multiple influenza subtypes of both phylogenetic group 1 and phylogenetic group 2 and can be used in combination with a chemical compound. Thus, the composition of the present invention is very useful for the prevention and treatment of a disease by influenza virus.

Composition comprising at least two influenza A virus-neutralizing-binding molecules

This invention relates to an adjuvant composition containing at least one binding molecule for neutralizing influenza virus and a vaccine composition containing the same. The composition containing at least one binding molecule for neutralizing influenza virus is capable of increasing the effects of a vaccine, and can thus be used as an adjuvant, which increases an immune response upon vaccine administration, and is very useful in the prevention of diseases caused by viruses.

Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same

The present invention relates to an epitope specific to hepatitis B virus surface antigen and a binding molecule binding to the same for neutralizing hepatitis B virus. Since the epitope provided by the present invention is produced by forming a three-dimensional structure and does not comprise a determinant, by which escape mutation is induced against an administration of existing vaccines or HBIg, a composition comprising an antibody biding to the epitope or a vaccine composition comprising the epitope has a very low possibility of causing a decrease in efficacy due to escape mutation. Therefore, such an antibody or vaccine composition can be very effectively used in prevention and/or treatment of HBV.

Epitope of hepatitis B virus surface antigen and binding molecule specifically binding to same for neutralizing hepatitis B virus

The present invention provides a stable peptide-conjugated, ascorbic acid derivative, a method for preparing the same, and a cosmetic composition comprising the same as an active ingredient. The stable peptide-conjugated ascorbic acid derivative of the present invention has both the effect of whitening the skin by inhibiting melanin production and the effect of reducing skin wrinkles by activating collagen production, and may be used in a cosmetic composition.

Stable peptide-conjugated ascorbic acid derivative, method for preparing same, and cosmetic composition comprising same

The present invention relates to a binding molecule having influenza A virus-neutralizing activity derived from a human B cell, and the binding molecule having the influenza A virus-neutralizing activity, according to the present invention, is a binding molecule that is derived from a B cell that is selected from the blood of a patient infected with an influenza A virus, and has neutralizing activity against influenza A viruses, and thus is useful in preventing and treating disease derived from the influenza A virus, and can be useful in diagnosing the influenza A virus by using the binding molecule according to the present invention.

Binding molecule having influenza A virus-neutralizing activity produced from human B cell

The present invention relates to human monoclonal antibodies derived from human B cells present in the blood of patients who had recovered from infection with influenza A viruses, wherein the monoclonal antibodies have neutralizing activity against influenza A viruses. The anti-influenza A virus monoclonal antibody of the present invention has binding and neutralizing activities against at least one influenza A virus selected from the group consisting of influenza A virus H1, H2 and H5 subtypes, and thus it is useful for the prevention and treatment of a disease caused by the influenza A virus and is also useful for diagnosis of influenza A virus infection.

Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses

Growing community of inventors

Incheon, South Korea

Shin Jae Chang